ducovest

UNC0:F:F-UCB S.A. UNSP.ADR 1/2 (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 62.5

Change

0.00 (0.00)%

Market Cap

USD 23.00B

Volume

4.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Currency: EUR

Country : Germany

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

N/A

 USD 519.71B
VX1:F Vertex Pharmaceuticals Incorpo..

N/A

 USD 101.21B
RGO:F Regeneron Pharmaceuticals Inc

N/A

 USD 100.87B
CSJ:F CSL Limited

N/A

 USD 81.66B
CSJA:F CSL LTD SPON.ADR 2

N/A

 USD 78.61B
0QF:F Moderna Inc

N/A

 USD 41.83B
UNC:F UCB SA

N/A

 USD 22.55B
1AE:F Argen-X

N/A

 USD 20.84B
1AEA:F argenx SE

N/A

 USD 20.80B
22UA:F BioNTech SE

N/A

 USD 20.71B

ETFs Containing UNC0:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 64.47% 90% A- 96% N/A
Dividend Return 1.91% 69% C- 52% F
Total Return 66.38% 90% A- 92% A
Trailing 12 Months  
Capital Gain 48.81% 85% B 89% A-
Dividend Return 1.73% 31% F 17% F
Total Return 50.54% 85% B 83% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.15% 77% C+ 68% D+
Dividend Return 6.16% 77% C+ 62% D
Total Return 0.00% 11% F N/A F
Risk Return Profile  
Volatility (Standard Deviation) 12.89% 87% B+ 75% C
Risk Adjusted Return 47.75% 91% A- 76% C+
Market Capitalization 23.00B 99% N/A 93% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.